performance of personnel in the capital market. These initiatives fall under the Strong Securities Issuers Project and focus on preventing, deterring and suppressing inappropriate behaviors and misconduct. A

Company Profile - JSP PHARMACEUTICAL MANUFACTURING (THAILAND) PUBLIC COMPANY LIMITED สำนักงานคณะกรรมการกำกับหลักทรัพย์และตลาดหลักทรัพย์ Printed on 09 August 2024 20:12 Company Profile JSP

further acquire the remaining 26% equity stake in PT. Indorama Petrochemicals (“PTIP”), a PTA manufacturing plant in Indonesia from PT. Indo-Rama Synthetics Tbk., a connected party. Rationale of the

million, increased 41.4% over the same period last year and increased 21.0% over last quarter due to strong customer demand in cloud storage and data center-related products such as Critical Infrastructure

Reported EPS less Inventory gains/(losses) less one-time extraordinary items Indorama Ventures 3rd Quarter 2018 MD&A 3 Financial Highlights IVL continued its strong performance in 3Q 2018, with growth in

solution and other medical product manufacturing and trading business. Previously the company held 44% of all shares. Later in February 2018, the company acquired additional shares from one of the

geographies. This performance reflects strong demand for our products, structurally higher margins and utilization rates, and the results of our long-term investment strategy. The business remains focused to

major customers, new model launch and new product launch led to higher revenues. Thailand operations were very strong; recording 68.3% growth year-on-year. China and Portugal operation were also strong

streamlining the offers of prepaid packages. Broadband and Enterprise business remains a strong growth engine Broadband revenue maintained its growth momentum with an increased subscriber base amid a price

sectors. Tourism was heavily affected by airspace and border closures, while merchandise exports fell sharply as demand from major trading partners fell, impacting both manufacturing production and domestic